Skip to content

The Efficacy of an Esketamine-Dexmedetomidine Regimen for Postoperative Analgesia Following Laparoscopic Total Hysterectomy

The Efficacy of an Esketamine-Dexmedetomidine Regimen for Postoperative Analgesia Following Laparoscopic Total Hysterectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114391
Enrollment
Unknown
Registered
2025-12-11
Start date
2024-09-26
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Management Optimization and Rehabilitation

Interventions

Intervention Group:Postoperative pain control can be initiated immediately using a patient-controlled intravenous analgesia (PCIA) pump with a combination of esketamine and dexmedetomidine
Control Group :Postoperative pain control can be initiated immediately using a patient-controlled intravenous analgesia (PCIA) pump with a combination of sufentanil and dexmedetomidine

Sponsors

Lu'an Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients selected for laparoscopic hysterectomy under general anesthesia at our hospital; 2. Age 45–70 years old; 3. ASA classification I–III; 4. Normal cognitive and communication abilities; 5. Informed consent given and voluntary participation in the study.

Exclusion criteria

Exclusion criteria: 1. Refusal to participate in the experiment; 2. Allergy or adverse reaction to the drug being studied; 3. Severe cardiac, pulmonary, or organ dysfunction; 4. Chronic pain or recent use of analgesics, mental disorders, or alcohol/drug abuse; psychiatric disorders such as epilepsy or a history of mental illness (bipolar disorder, schizophrenia, etc.); 5. Severe hypertension: patients with grade 3 or higher hypertension or poorly controlled blood pressure; 6. High intraocular pressure: patients with glaucoma; 7. Significant organ dysfunction; 8. Myocardial infarction or congestive heart failure in the past 6 months; 9. Allergies to components of the study medication; 10. Terminal malignant tumors, communication disorders, or inability to correctly understand the investigator's questions.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;Ramsay Sedation Scale scores;State Anxiety Inventory (SAI)and Beck Depression Inventory (BDI);Pittsburgh Sleep Quality Index (PSQI) ;Quality of Recovery-40 (QoR-40) scale;

Countries

China

Contacts

Public ContactZhonghou Xu; Wenxiu Wang

Lu'an Hospital of Anhui Medical University

2056161544@qq.com+86 139 6549 4791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026